Bylvay

Active Ingredient(s): Odevixibat
FDA Approved: * July 20, 2021
Pharm Company: * ALBIREO
Category: Genetic Disorders

Odevixibat, sold under the trade name Bylvay, is a medication for the treatment of progressive familial intrahepatic cholestasis (PFIC).[1][4] It is taken by mouth.[1] The most common side effects include diarrhea, abdominal pain, hemorrhagic diarrhea, soft feces, and hepatomegaly (enlarged liver).[4] Odevixibat is a reversible, potent, selective inhibitor of the ileal bile acid transporter (IBAT).[4][5&am... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Bylvay 200 ug/1 Oral Capsule, Coated Pellets
NDC: 15054-3301
Labeler:
Ipsen Biopharmaceuticals, Inc.
Bylvay 400 ug/1 Oral Capsule
NDC: 15054-3302
Labeler:
Ipsen Biopharmaceuticals, Inc.
Bylvay 600 ug/1 Oral Capsule, Coated Pellets
NDC: 15054-3303
Labeler:
Ipsen Biopharmaceuticals, Inc.
Bylvay 1200 ug/1 Oral Capsule
NDC: 15054-3304
Labeler:
Ipsen Biopharmaceuticals, Inc.
Bylvay 200 ug/1 Oral Capsule, Coated Pellets
NDC: 74528-020
Labeler:
Albireo Pharma, Inc.
Bylvay 400 ug/1 Oral Capsule, Coated Pellets
NDC: 74528-040
Labeler:
Albireo Pharma, Inc.
Bylvay 600 ug/1 Oral Capsule, Coated Pellets
NDC: 74528-060
Labeler:
Albireo Pharma, Inc.
Bylvay 1200 ug/1 Oral Capsule, Coated Pellets
NDC: 74528-120
Labeler:
Albireo Pharma, Inc.